Translational Therapeutics, Inc. is an IND-ready pharmaceutical company based in the Boston metropolitan area.
Our Work We are focused on developing an integrated set of novel therapeutics and diagnostics that provide for the safe, and effective targeted diagnosis and treatment of cancers caused by the oncogene eIF4E (4E Cancers).
Why 4E Cancers? There is currently no effective medical standard of care for 4E Cancers. 4E Cancers are generally high grade, metastatic and have a poor prognosis. 4E Cancers represent 25% of all cancers (US: 500K cases/year) and 60% of all cancer deaths (US: 350K deaths/year).
How does our therapeutic agent work? Our lead therapeutic agent targets a central 'gating' function active in the cancerous process (eIF4E). In short, when the gate is open = bad. And when the gate is closed = good. The good news is that our therapeutic closes the gate!
In addition to broad mono-therapeutic applications, our agent can be used in combination with a wide variety of existing therapeutics as well as in concert with or as a small molecule replacement for immuno-therapeutics.
Where are we now? We have established our regulatory strategy and manufacturing pipeline and are ready to initiate a Phase I/IIa clinical trial to confirm our therapeutic system's clinical and biological efficacy in an orphan indication.
What People are Saying Two corporate venture partners comments: "Great target" and "Program significantly de-risked"
Michael Kauffman, CEO Karyopharm: “We believe that eIF4E is a compelling cancer relevant target and that Translational Therapeutics has an efficient path to proof-of-concept that could lead to a completely novel therapy which should have both single agent activity and enhance other therapies with a good tolerability profile.”
Thank you for your interest - Please contact us to learn more.
Gordon A. Jamieson, Jr. MBA PhD CEO and Founder
Translational Therapeutics, Inc. 163 Scituate Street Arlington, MA 02476 781.483.3266 firstname.lastname@example.org